# Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

> **NCT03587662** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Metastatic Kidney Medullary Carcinoma
- Metastatic Renal Cell Carcinoma
- SMARCB1 Negative
- Stage III Renal Cell Cancer AJCC v8
- Stage IV Renal Cell Cancer AJCC v8

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Gemcitabine
- **DRUG:** Gemcitabine Hydrochloride
- **DRUG:** Ixazomib
- **DRUG:** Ixazomib Citrate

## Key facts

- **NCT ID:** NCT03587662
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-17
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03587662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03587662, "Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03587662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*